146 related articles for article (PubMed ID: 9500186)
1. Oral versus intraperitoneal administration of irinotecan in the treatment of human neuroblastoma in nude mice.
Choi SH; Tsuchida Y; Yang HW
Cancer Lett; 1998 Feb; 124(1):15-21. PubMed ID: 9500186
[TBL] [Abstract][Full Text] [Related]
2. Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno-transplanted neuroblastoma.
Komuro H; Li P; Tsuchida Y; Yokomori K; Nakajima K; Aoyama T; Kaneko M; Kaneda N
Med Pediatr Oncol; 1994; 23(6):487-92. PubMed ID: 7935175
[TBL] [Abstract][Full Text] [Related]
3. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts.
Zamboni WC; Houghton PJ; Thompson J; Cheshire PJ; Hanna SK; Richmond LB; Lou X; Stewart CF
Clin Cancer Res; 1998 Feb; 4(2):455-62. PubMed ID: 9516936
[TBL] [Abstract][Full Text] [Related]
4. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
[TBL] [Abstract][Full Text] [Related]
5. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice.
Stewart CF; Zamboni WC; Crom WR; Houghton PJ
Cancer Chemother Pharmacol; 1997; 40(3):259-65. PubMed ID: 9219511
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.
Kawato Y; Furuta T; Aonuma M; Yasuoka M; Yokokura T; Matsumoto K
Cancer Chemother Pharmacol; 1991; 28(3):192-8. PubMed ID: 1855276
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice.
Guichard S; Chatelut E; Lochon I; Bugat R; Mahjoubi M; Canal P
Cancer Chemother Pharmacol; 1998; 42(2):165-70. PubMed ID: 9654118
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats.
Machida Y; Onishi H; Kurita A; Hata H; Morikawa A; Machida Y
J Control Release; 2000 May; 66(2-3):159-75. PubMed ID: 10742577
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration.
Ahn BJ; Choi MK; Park YS; Lee J; Park SH; Park JO; Lim HY; Kang WK; Ko JW; Yim DS
Eur J Clin Pharmacol; 2010 Dec; 66(12):1235-45. PubMed ID: 20827550
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of oral irinotecan against neuroblastoma xenografts.
Thompson J; Zamboni WC; Cheshire PJ; Richmond L; Luo X; Houghton JA; Stewart CF; Houghton PJ
Anticancer Drugs; 1997 Apr; 8(4):313-22. PubMed ID: 9180383
[TBL] [Abstract][Full Text] [Related]
11. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
Zamboni WC; Stewart CF; Cheshire PJ; Richmond LB; Hanna SK; Luo X; Poquette C; McGovren JP; Houghton JA; Houghton PJ
Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544
[TBL] [Abstract][Full Text] [Related]
12. Influence of route of administration on [3H]-camptothecin distribution and tumor uptake in CASE-bearing nude mice: whole-body autoradiographic studies.
Ahmed AE; Jacob S; Giovanella BC; Kozielski AJ; Stehlin JS; Liehr JG
Cancer Chemother Pharmacol; 1996; 39(1-2):122-30. PubMed ID: 8995509
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of CPT-11, a camptothecin derivative, on human testicular tumor xenografts in nude mice.
Miki T; Sawada M; Nonomura N; Kojima Y; Okuyama A; Maeda O; Saiki S; Kotake T
Eur Urol; 1997; 31(1):92-6. PubMed ID: 9032542
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
Thompson J; Zamboni WC; Cheshire PJ; Lutz L; Luo X; Li Y; Houghton JA; Stewart CF; Houghton PJ
Clin Cancer Res; 1997 Mar; 3(3):423-31. PubMed ID: 9815701
[TBL] [Abstract][Full Text] [Related]
15. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice.
Vassal G; Boland I; Santos A; Bissery MC; Terrier-Lacombe MJ; Morizet J; Sainte-Rose C; Lellouch-Tubiana A; Kalifa C; Gouyette A
Int J Cancer; 1997 Sep; 73(1):156-63. PubMed ID: 9334824
[TBL] [Abstract][Full Text] [Related]
16. [Liver concentration of CPT-11, SN-38 and SN-38 GLU in intraperitoneal and intravenous administration of CPT-11].
Maruyama M; Nagahama T; Yuasa Y
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1967-9. PubMed ID: 10560438
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma.
Jansen WJ; Kolfschoten GM; Erkelens CA; Van Ark-Otte J; Pinedo HM; Boven E
Int J Cancer; 1997 Dec; 73(6):891-6. PubMed ID: 9399672
[TBL] [Abstract][Full Text] [Related]
18. Non-linear pharmacokinetics of irinotecan in mice.
Rouits E; Guichard S; Canal P; Chatelut E
Anticancer Drugs; 2002 Jul; 13(6):631-5. PubMed ID: 12172509
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
Vassal G; Terrier-Lacombe MJ; Bissery MC; Vénuat AM; Gyergyay F; Bénard J; Morizet J; Boland I; Ardouin P; Bressac-de-Paillerets B; Gouyette A
Br J Cancer; 1996 Aug; 74(4):537-45. PubMed ID: 8761367
[TBL] [Abstract][Full Text] [Related]
20. Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors.
Hattori Y; Shi L; Ding W; Koga K; Kawano K; Hakoshima M; Maitani Y
J Control Release; 2009 May; 136(1):30-7. PubMed ID: 19331859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
